LY4170156 + carboplatin

This is an **experimental combination therapy** consisting of LY4170156, an Fc-attenuated humanized IgG1 antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), conjugated with a novel polysarcosine hydrophilic masking entity allowing an exatecan payload (drug-antibody ratio, DAR 8), **combined with carboplatin**, a platinum-based chemotherapeutic agent. The combination is being studied for safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced solid tumors, especially those expressing FRα. The primary indications in ongoing trials include ovarian (including epithelial ovarian, primary peritoneal, and fallopian tube), endometrial, cervical, non-small cell lung, triple-negative breast, pancreatic, and colorectal cancers. Development is at the phase 1 level, with arms evaluating monotherapy as well as combinations with established chemotherapies, such as carboplatin and bevacizumab. The combination is administered intravenously[1][3][6][5].